Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...

Although coverage restrictions remain in place, the trendiness of weight loss drugs may be creating a growing cost concern ...

Are you weening yourself off a compounded version of the drug? Considering switching insurers in order to keep your ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Guggenheim analyst Jason Cassorla maintained a Buy rating on Cigna (CI – Research Report) today and set a price target of $388.00. The company’s shares closed yesterday at $31 ...

Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost nearly 50% more weight, on average, than Wegovy ones did.

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

The GLP-1 drugs are currently only covered by half of The Cigna Group ... its preferred weight-loss medication. According to analysts, net discounts for employers on list prices range from ...